These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 19381445

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
    Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, Weller M.
    Neuro Oncol; 2009 Dec; 11(6):747-56. PubMed ID: 19221171
    [Abstract] [Full Text] [Related]

  • 3. Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
    Li XQ, Ouyang ZG, Zhang SH, Liu H, Shang Y, Li Y, Zhen YS.
    Cancer Biol Ther; 2014 Apr; 15(4):398-408. PubMed ID: 24424202
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
    Ulasov I, Thaci B, Sarvaiya P, Yi R, Guo D, Auffinger B, Pytel P, Zhang L, Kim CK, Borovjagin A, Dey M, Han Y, Baryshnikov AY, Lesniak MS.
    Cancer Med; 2013 Aug; 2(4):457-67. PubMed ID: 24156018
    [Abstract] [Full Text] [Related]

  • 5. Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide.
    Chai KM, Wang CY, Liaw HJ, Fang KM, Yang CS, Tzeng SF.
    Oncotarget; 2014 Nov 15; 5(21):10901-15. PubMed ID: 25337721
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG, Marand SV, Geraci S, Pycroft L, Berger FR, Pelletier LA.
    Oncotarget; 2015 Oct 06; 6(30):29456-68. PubMed ID: 26336131
    [Abstract] [Full Text] [Related]

  • 7. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N, Agasse F, Armstrong D, Peng L, Commins D, Wang W, Rosenstein-Sisson R, Vaikari VP, Santiago SV, Santos T, Chen L, Schönthal AH, Chen TC, Hofman FM.
    Cancer Lett; 2016 Feb 28; 371(2):240-50. PubMed ID: 26683773
    [Abstract] [Full Text] [Related]

  • 8. Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
    Cho HY, Wang W, Jhaveri N, Torres S, Tseng J, Leong MN, Lee DJ, Goldkorn A, Xu T, Petasis NA, Louie SG, Schönthal AH, Hofman FM, Chen TC.
    Mol Cancer Ther; 2012 Nov 28; 11(11):2462-72. PubMed ID: 22933703
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
    Ohba S, Hirose Y, Kawase T, Sano H.
    J Neurooncol; 2009 Dec 28; 95(3):307-316. PubMed ID: 19517066
    [Abstract] [Full Text] [Related]

  • 10. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
    Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E.
    Int J Oncol; 2009 Jul 28; 35(1):139-48. PubMed ID: 19513561
    [Abstract] [Full Text] [Related]

  • 11. Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
    Xu GW, Mymryk JS, Cairncross JG.
    Int J Cancer; 2005 Aug 20; 116(2):187-92. PubMed ID: 15800902
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
    Li S, Zeng A, Hu Q, Yan W, Liu Y, You Y.
    Neuro Oncol; 2017 Jan 20; 19(1):55-65. PubMed ID: 27471108
    [Abstract] [Full Text] [Related]

  • 15. Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway.
    Han S, Li Z, Master LM, Master ZW, Wu A.
    Br J Cancer; 2014 Sep 23; 111(7):1400-9. PubMed ID: 25093489
    [Abstract] [Full Text] [Related]

  • 16. Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro.
    Gao S, Yang XJ, Zhang WG, Ji YW, Pan Q.
    Chin Med J (Engl); 2009 Jun 05; 122(11):1260-6. PubMed ID: 19567134
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
    Lu XY, Cao K, Li QY, Yuan ZC, Lu PS.
    J Int Med Res; 2012 Jun 05; 40(3):995-1004. PubMed ID: 22906272
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.